Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
35.87
+8.02 (28.80%)
At close: Mar 6, 2026, 4:00 PM EST
35.75
-0.12 (-0.33%)
After-hours: Mar 6, 2026, 7:59 PM EST
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
673.52M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Rigel Pharmaceuticals | 294.28M |
| Fulcrum Therapeutics | 80.00M |
| ADC Therapeutics | 75.21M |
| Verastem | 30.91M |
| Prothena Corporation | 9.68M |
| Allogene Therapeutics | 22.00K |
TECX News
- 21 hours ago - Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 8 days ago - Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 11 days ago - Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board - GlobeNewsWire
- 23 days ago - Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 - GlobeNewsWire
- 3 months ago - Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point - Seeking Alpha
- 4 months ago - Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript - Seeking Alpha
- 4 months ago - Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF - GlobeNewsWire
- 6 months ago - Tectonic Therapeutic to Participate in September Investor Conferences - GlobeNewsWire